Pericarditis clinical trials at UC Irvine

2 research studies open to eligible people

Showing trials for

  • CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

    open to eligible people ages 18 years and up

    Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.

    Irvine, California and other locations

  • VTX2735 in Recurrent Pericarditis

    open to eligible people ages 18-75

    This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: - A 30-day Screening Period (to see if a participant qualifies for the study) - A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A - A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A - An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B - A 14-day Follow-Up Period Cohort B will include approximately 20 participants and will consist of the following: - A 30-day Screening Period (to see if a participant qualifies for the study) - A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C - An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C - A 14-day Follow-Up Period Cohort C will include approximately 20 participants and will consist of the following: - A 30-day Screening Period (to see if a participant qualifies for the study) - A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B - An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B - A 14-day Follow-Up Period

    Orange, California and other locations

Our lead scientists for Pericarditis research studies include .

Last updated: